Abstract
Neoadjuvant chemotherapy (NAC) using 5-FU (5-fluorouracil)/CDDP (cisplatin) is a standard therapy for stage II/III thoracic esophageal squamous cell carcinoma (ESCC) in Japan. The aim of this study was to investigate whether 5-FU/CDDP could induce immunogenic cell death in ESCC cell lines. Tumor samples for immunohistochemistry were obtained from 50 patients (mean age=63.1 years) with pathological stage 0-IVa ESCC who underwent NAC followed by surgery. Cell lines T.T and KYSE30 were used for the in vitro experiments. The concentrations of HMGB1 were elevated in the cell line supernatants treated with 5-FU/CDDP. 5-FU/CDDP treated dendritic cells (DCs) showed a mature phenotype, and enhanced T cell proliferation capacity. In addition, mature DCs were observed in surgical specimens with a histological response after treatment with 5-FU/CDDP chemotherapy. 5-FU/CDDP could induce immunogenic cell death in the tumor microenvironment of ESCC.
Highlights
JUNYA NISHIMURA*, SOTA DEGUCHI*, HIROAKI TANAKA, YOSHIHITO YAMAKOSHI, MAMI YOSHII, TATSURO TAMURA, TAKAHIRO TOYOKAWA, SHIGERU LEE, KAZUYA MUGURUMA and MASAICHI OHIRA
We found that infiltration of lysosome-associated membrane glycoprotein 3 (LAMP-3) dendritic cells (DCs) was increased in 32 cases with any histological changes
CDDP, which are key drugs used as neoadjuvant chemotherapy for esophageal squamous cell carcinoma (ESCC)
Summary
The aim of this study was to investigate whether 5-FU/CDDP could induce immunogenic cell death in ESCC cell lines.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
